MTOR and central nervous system cancer: Furthermore, NVP-BEZ235 (a dual mTOR and PI3K inhibitor currently being tested in clinical trials) induced autophagy in solid tumors, and synergistically acted in combination with CQ through increased apoptosis in glioma cells [200].